Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revance Therapeutics Inc RVNC

Healthcare
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to... see more

Recent & Breaking News (NDAQ:RVNC)

RVNC Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Revance Therapeutics, Inc. Investors of Class Action and Lead Plaintiff Deadline: February 8, 2022

Newsfile February 3, 2022

Kessler Topaz Meltzer & Checker, LLP: Final Deadline Reminder for Revance Therapeutics, Inc. (RVNC) Investors

Newsfile February 3, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - RVNC

Newsfile February 2, 2022

Revance Therapeutics Shareholder Alert

Newsfile February 2, 2022

RVNC LAWSUIT ALERT: Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

PR Newswire February 2, 2022

Tuesday Deadline Reminder: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile February 2, 2022

Lead Plaintiff Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Revance Therapeutics, Inc.

Newsfile February 1, 2022

Revance Therapeutics Deadline Alert

Newsfile February 1, 2022

RVNC ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 8, 2022 in the Class Action Filed on Behalf of Revance Therapeutics, Inc. Limited Shareholders

PR Newswire February 1, 2022

RVNC Alert: Thornton Law Firm Reminds Revance Therapeutics Investors of Securities Class Action

Newsfile February 1, 2022

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Revance Investors of a Lead Plaintiff Deadline of February 8, 2022

PR Newswire January 31, 2022

RVNC Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC, a Nationally Recognized Firm, Reminds Revance Therapeutics, Inc. Investors of Class Action and Lead Plaintiff Deadline: February 8, 2022

Newsfile January 31, 2022

Upcoming Deadline Alert: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile January 31, 2022

Revance Therapeutics Update

Newsfile January 30, 2022

SECURITIES CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds RVNC Investors of Upcoming Deadline and Urges Investors with Substantial Losses to Contact the Firm

PR Newswire January 29, 2022

(RVNC) DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel About Leading Revance Therapeutics Class Action Lawsuit

Newsfile January 29, 2022

Revance Therapeutics Class Action Reminder

Newsfile January 29, 2022

Upcoming Deadline Reminder: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile January 28, 2022

RVNC SHAREHOLDER ALERT: Jakubowitz Law Reminds Revance Shareholders of a Lead Plaintiff Deadline of February 8, 2022

PR Newswire January 28, 2022

Investor Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Revance Therapeutics, Inc. (RVNC)

Newsfile January 28, 2022